Kunming High-tech Industrial Development Zone vowed to intensify its efforts to promote industrial development related to bio-medicine, precious metals and the digital economy and strive to achieve high-quality development with the fast expansion of its economy.
A new cosmetic manufacturing base with investment from Botanee Group is scheduled to be introduced this March. The production center has received relevant licenses and approvals.
Botanee Group has attached great importance to sci-tech innovation and green development and is looking forward to building a digital factory in the next three to five years.
Kun Zhong Yao is a Traditional Chinese Medicine (TCM) pharmaceutical with a history of over 600 years. Its annual revenue has surpassed three billion yuan ($438.2 million) over the past three years.
Jin Ling, deputy head of the company, said that its industrial profits are set to increase by 1.6 billion yuan amid its fast business expansion this year.
Right now, the high-tech industrial development zone has accommodated the settlement of many famous pharmaceutical companies and their revenues have accounted for nearly two thirds of the total.
The high-tech industrial development zone will step up its efforts in the building of a vaccine production center, a technological upgrading project of KPC Pharmaceuticals in the utilization of natural plants to produce raw medical materials, and the second phase of Yunnan Shengke Pharmaceuticals. The goal is to foster new economic growth and help the bio-medicine industrial sector grow by over 15 percent on a yearly basis.
Meanwhile, the high-tech industrial development zone will endeavor to make its precious metals and digital economy sectors rise by over 12 percent and 20 percent respectively through the accelerated development of leading projects.
During an interview, Zhang Wei, head of the department for economic development in the high-tech industrial zone, introduced that it will pool more human resource and capital into technological innovation and sci-tech research, promote commercialization of research results, consolidate and expand industrial chains, bolster its capabilities in creating more added values and enhance the efficacy of industrial output, and achieve healthy growth.
